Synaptic oligomeric tau in Alzheimer's disease - A potential culprit in the spread of tau pathology through the brain
- PMID: 37192625
- DOI: 10.1016/j.neuron.2023.04.020
Synaptic oligomeric tau in Alzheimer's disease - A potential culprit in the spread of tau pathology through the brain
Abstract
In Alzheimer's disease, fibrillar tau pathology accumulates and spreads through the brain and synapses are lost. Evidence from mouse models indicates that tau spreads trans-synaptically from pre- to postsynapses and that oligomeric tau is synaptotoxic, but data on synaptic tau in human brain are scarce. Here we used sub-diffraction-limit microscopy to study synaptic tau accumulation in postmortem temporal and occipital cortices of human Alzheimer's and control donors. Oligomeric tau is present in pre- and postsynaptic terminals, even in areas without abundant fibrillar tau deposition. Furthermore, there is a higher proportion of oligomeric tau compared with phosphorylated or misfolded tau found at synaptic terminals. These data suggest that accumulation of oligomeric tau in synapses is an early event in pathogenesis and that tau pathology may progress through the brain via trans-synaptic spread in human disease. Thus, specifically reducing oligomeric tau at synapses may be a promising therapeutic strategy for Alzheimer's disease.
Keywords: Alzheimer; synapse; tau.
Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests T.S.-J. is on the Scientific Advisory Board of Cognition Therapeutics and has received honoraria for talks for industry collaborators. They did not have any involvement in or influence over the current paper. T.S.-J. is also a member of the Neuron Editorial Advisory Board.
Comment in
-
Oligomeric tau might spread trans-synaptically in Alzheimer disease.Nat Rev Neurosci. 2023 Jul;24(7):393. doi: 10.1038/s41583-023-00714-9. Nat Rev Neurosci. 2023. PMID: 37237104 No abstract available.
-
Oligomeric tau could spread through synapses in AD.Nat Rev Neurol. 2023 Jul;19(7):385. doi: 10.1038/s41582-023-00831-0. Nat Rev Neurol. 2023. PMID: 37258722 No abstract available.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
